ArticlePloS one2011
Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 83 citations in OpenAlex.
- Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review.The British journal of dermatology · 2026Article
- Clinical Significance of SDC2 in Gastric Cancer: Insights From a Multi-Center Cohort Study.Cancer informatics · 2026Article
- Spatial transcriptomics reveal high T cell and monocyte status as predictive and prognostic markers in pancreatic cancer.Journal of translational medicine · 2025Article
- Off-The-Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Ferroptosis contributes to immunosuppression.Frontiers of medicine · 2025Review
- By integrating single-cell RNA sequencing and bulk RNA sequencing, plasma cells signature and tertiary lymphoid structures were verified to contribute to outcome in lung adenocarcinoma.Translational cancer research · 2025Article
- Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients.Frontiers in immunology · 2025Article
- Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor.Exploration of targeted anti-tumor therapy · 2025Review
- Oxidized Melanoma Antigens Promote Activation and Proliferation of Cytotoxic T-Cell Subpopulations.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A Narrative Review: Immunometabolic Interactions of Host-Gut Microbiota and Botanical Active Ingredients in Gastrointestinal Cancers.International journal of molecular sciences · 2024Review
- Determinants of resistance and response to melanoma therapy.Nature cancer · 2024Review
- Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2024Article
- Role of Serotonergic System in Regulating Brain Tumor-Associated Neuroinflammatory Responses.Methods in molecular biology (Clifton, N.J.) · 2024Article
- From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy.Frontiers in immunology · 2024Review
- The unique properties of IgG4 and its roles in health and disease.Nature reviews. Immunology · 2023Review
- Review
- Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants.Drug delivery and translational research · 2023Article
- Tumor-Infiltrating B Lymphocytes: Promising Immunotherapeutic Targets for Primary Liver Cancer Treatment.Cancers · 2023Review
- Multicellular network analysis of melanoma heterogeneity by scRNA-seq.American journal of translational research · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 2 countries.
Funding
Abstract
Melanoma, a potentially lethal skin cancer, is widely thought to be immunogenic in nature. While there has been much focus on T cell-mediated immune responses, limited knowledge exists on the role of mature B cells. We describe an approach, including a cell-based ELISA, to evaluate mature IgG antibody responses to melanoma from human peripheral blood B cells. We observed a significant increase in antibody responses from melanoma patients (n = 10) to primary and metastatic melanoma cells compared to healthy volunteers (n = 10) (P<0.0001). Interestingly, we detected a significant reduction in antibody responses to melanoma with advancing disease stage in our patient cohort (n = 21) (P<0.0001). Overall, 28% of melanoma patient-derived B cell cultures (n = 1,800) compared to 2% of cultures from healthy controls (n = 600) produced antibodies that recognized melanoma cells. Lastly, a patient-derived melanoma-specific monoclonal antibody was selected for further study. This antibody effectively killed melanoma cells in vitro via antibody-mediated cellular cytotoxicity. These data demonstrate the presence of a mature systemic B cell response in melanoma patients, which is reduced with disease progression, adding to previous reports of tumor-reactive antibodies in patient sera, and suggesting the merit of future work to elucidate the clinical relevance of activating humoral immune responses to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.